Veloxis Pharmaceuticals has administered the first dose of pegrizeprument (VEL-101) in the Phase 2 RENGEVITY-201 study, which aims to prevent organ rejection in kidney transplant recipients. The trial will evaluate the drug’s safety and efficacy in this patient population.
Veloxis Pharmaceuticals, a global specialty pharmaceutical company part of Asahi Kasei Corporation, announced that it will present five poster presentations at the American Transplant Congress (ATC) scheduled for June 20-24, 2026 in Boston, Massachusetts. The presentations will highlight the company's research aimed at improving the lives of transplant and other immunocompromised patients.
Veloxis Pharmaceuticals announced that pegrizeprument (VEL-101), an investigational maintenance immunosuppressive agent, received Orphan Drug Designation from the U.S. Food and Drug Administration for preventing organ rejection in heart transplant patients.
Asahi Kasei announced that it has completed its acquisition of Aicuris, whose three antiviral assets complement Asahi Kasei’s therapy portfolio. Aicuris revenue is expected to reach $500 million by 2030. The FDA has granted Priority Review to pritelivir’s New Drug Application, with a PDUFA target date in Q4 2026.
Veloxis Pharmaceuticals announced that pegrizeprument (VEL-101) has been granted orphan drug designation for the prevention of organ rejection in patients receiving a liver transplant. The drug is a novel investigational maintenance immunosuppressive agent under development.
Veloxis Pharmaceuticals will present new preclinical data on pegrizeprument (VEL-101) at the 2025 World Transplant Congress. The novel subcutaneous CD28 co-stimulation blocker is being developed as maintenance immunosuppression for kidney transplantation.
Veloxis Pharmaceuticals announced that the USAN Council approved “pegrizeprument” as the nonproprietary name for VEL-101, its lead transplant candidate.
Veloxis Pharmaceuticals announced that research on VEL-101, also known as FR104, will be presented at the 2024 American Transplant Congress in Philadelphia. VEL-101 is an investigational maintenance immunosuppressive agent.
Veloxis Pharmaceuticals Chief Scientific Officer Ulf Meier-Kriesche, MD, FAST, will receive the National Kidney Foundation’s Market Innovation Award at its first annual North Carolina Honors Reception, scheduled for March 28, 2024.
Veloxis Pharmaceuticals is the premier sponsor of Donate Life North Carolina’s 2023 Gift of Life Gala: heART of the Matter. The event raises funds for organ, eye and tissue donation outreach and education in North Carolina.